NCT00050505View on ClinicalTrials.gov

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

927

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

December 31, 2003

Conditions
Smallpox
Interventions
BIOLOGICAL

Live vaccinia virus vaccine

Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine

BIOLOGICAL

Live vaccinia virus vaccine

Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.

Trial Locations (7)

14642

University of Rochester, Rochester

21201

University of Maryland Baltimore, Baltimore

27704

Duke Health Center, Durham

63110

Saint Louis University, St Louis

90502

UCLA Center For Vaccine Research, Torrance

94612

Kaiser Permanente Vaccine Study Center, Oakland

94305-5208

Stanford University, Stanford

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00050505 - Expanded Dryvax Dilution Study in Previously Vaccinated Adults | Biotech Hunter | Biotech Hunter